Blaine Templeman Sells 3,557 Shares of Aduro Biotech, Inc. (ADRO) Stock
Aduro Biotech, Inc. (NASDAQ:ADRO) VP Blaine Templeman sold 3,557 shares of Aduro Biotech stock in a transaction dated Wednesday, September 13th. The shares were sold at an average price of $10.99, for a total transaction of $39,091.43. Following the transaction, the vice president now owns 65,275 shares of the company’s stock, valued at $717,372.25. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
Aduro Biotech, Inc. (NASDAQ:ADRO) traded up 0.90% on Thursday, reaching $11.15. 609,127 shares of the company traded hands. The stock’s 50 day moving average price is $11.67 and its 200 day moving average price is $10.97. The company’s market capitalization is $831.92 million. Aduro Biotech, Inc. has a one year low of $8.75 and a one year high of $15.52.
Aduro Biotech (NASDAQ:ADRO) last released its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported ($0.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.02). The firm had revenue of $5.90 million for the quarter, compared to the consensus estimate of $3.98 million. Aduro Biotech had a negative net margin of 609.58% and a negative return on equity of 43.92%. The firm’s revenue for the quarter was down 84.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.03 earnings per share. On average, equities research analysts predict that Aduro Biotech, Inc. will post ($1.37) EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This news story was posted by American Banking News and is owned by of American Banking News. If you are reading this news story on another domain, it was illegally copied and reposted in violation of US & international trademark and copyright law. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2017/09/14/blaine-templeman-sells-3557-shares-of-aduro-biotech-inc-adro-stock.html.
ADRO has been the subject of a number of analyst reports. Zacks Investment Research upgraded shares of Aduro Biotech from a “hold” rating to a “buy” rating and set a $13.00 price objective for the company in a report on Tuesday, July 4th. BidaskClub upgraded shares of Aduro Biotech from a “hold” rating to a “buy” rating in a report on Tuesday, July 25th. HC Wainwright set a $18.00 price objective on shares of Aduro Biotech and gave the company a “buy” rating in a report on Thursday, August 3rd. Cowen and Company initiated coverage on shares of Aduro Biotech in a report on Tuesday, July 18th. They set an “outperform” rating for the company. Finally, Canaccord Genuity set a $30.00 price objective on shares of Aduro Biotech and gave the company a “buy” rating in a report on Thursday, August 3rd. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and seven have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $19.00.
Large investors have recently added to or reduced their stakes in the business. Schwab Charles Investment Management Inc. increased its stake in Aduro Biotech by 5.7% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 145,112 shares of the biotechnology company’s stock valued at $1,560,000 after purchasing an additional 7,812 shares in the last quarter. Vanguard Group Inc. increased its stake in Aduro Biotech by 2.1% during the 1st quarter. Vanguard Group Inc. now owns 2,382,916 shares of the biotechnology company’s stock valued at $25,617,000 after purchasing an additional 48,840 shares in the last quarter. Piermont Capital Management Inc. bought a new stake in Aduro Biotech during the 1st quarter valued at about $386,000. Bank of New York Mellon Corp increased its stake in Aduro Biotech by 3.8% during the 1st quarter. Bank of New York Mellon Corp now owns 148,166 shares of the biotechnology company’s stock valued at $1,593,000 after purchasing an additional 5,470 shares in the last quarter. Finally, Goldman Sachs Group Inc. increased its stake in Aduro Biotech by 330.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 236,721 shares of the biotechnology company’s stock valued at $2,545,000 after purchasing an additional 181,734 shares in the last quarter. Institutional investors and hedge funds own 35.05% of the company’s stock.
Aduro Biotech Company Profile
Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.
Receive News & Ratings for Aduro Biotech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro Biotech Inc. and related companies with MarketBeat.com's FREE daily email newsletter.